Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Phico Therapeutics
Phico Therapeutics
Activities:
Research & Development
Infection Control
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Phico Therapeutics appoints Financial Director and two non-executives
Pharmaceutical
Phico Therapeutics awarded Innovate UK funding
The funding will support development of a <i>Pseudomonas aeruginosa</i> targeted therapeutic, to tackle the genetic cause of antibiotic resistance
Research & Development
Phico Therapeutics receives £2.25m grant to advance its SASPject PT4 towards clinical trials
The antibiotic is aimed at Escherichia coli and Klebsiella pneumoniae
Research & Development
Phico raises further funds to fight E.coli
To develop SASPject antibiotic technology
Research & Development
Phico Therapeutics raises £1.8m to advance new class of antibiotics
Technology could form the basis of a new class of antibiotics
Subscribe now